70% of medicines given to children have never been studied in pediatric populations. Children who need treatments represent a relatively small population. This alone presents unique challenges for pediatric drug development. Since the 1990s, authorities around the world have worked to solve these issues, enacting legislations to encourage pediatric drug development plans—but there is still more to do. This two-part paper discusses the role global collaboration will play in bringing life-changing drugs to children who need them most. Download to read Part Two or click here to read Part One.